Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer
A Phase 1 Study of TRAIL-R2 (DR5) Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer
Sponsor: Bristol-Myers Squibb
Terminated
Business Decision
A PHASE1 clinical study on Colorectal Neoplasm, this trial is terminated or withdrawn. The trial is conducted by Bristol-Myers Squibb and has accumulated 14 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Mar 2024 — Jul 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Mar 2024 [monthly]
Terminated PHASE1
▶ Show 9 earlier versions
-
Mar 2019 — Jan 2021 [monthly]
Terminated PHASE1
-
Jan 2019 — Mar 2019 [monthly]
Terminated PHASE1
-
Jun 2018 — Jan 2019 [monthly]
Terminated PHASE1
-
Oct 2017 — Jun 2018 [monthly]
Terminated PHASE1
Status: Active Not Recruiting → Terminated
-
Sep 2017 — Oct 2017 [monthly]
Active Not Recruiting PHASE1
-
Aug 2017 — Sep 2017 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Apr 2017 — Aug 2017 [monthly]
Recruiting PHASE1
-
Feb 2017 — Apr 2017 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Dec 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bristol-Myers Squibb
- Daiichi Sankyo
For direct contact, visit the study record on ClinicalTrials.gov .